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•	 Germline eGfr T790m 
Mutation found in 
Multiple Members of a 
familial Cohort
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well-differentiated primary lung adenocarcinoma, 
with concurrent somatic mutations (EGFR exon 19 
deletion, EGFR L858R, EGFR T790M, and ARID1A, 
which was recently found in lung adenocarcinoma). 
The presence of germline EGFR T790M is clinically 
linked to lung adenocarcinoma development and found 
in about half of all patients harboring baseline EGFR 
T790M in their tumor specimens before treatment. 
The authors recommended these patients be tested for 
germline EGFR T790M and suggested prospective 
studies on germline EGFR T790M mutation carriers to 
gain insights on the clinical significance of the mutation. 
According to the authors, their patients with germline 
EGFR T790M mutations showed bilateral ground-glass 
opacities and pulmonary nodules on radiographs. Two 
of four patients had indolent disease whereas the other 
two had more aggressive metastatic disease and died 
from their disease after chemotherapy. Evaluation of the 
concurrent somatic mutations and the germline carriers 
would help understand the oncogenic development 
from germline mutation carrier to clinically evident 
malignancy, which may ultimately help develop 
therapeutic interventions for this cohort. (p. 554)
•	 hereditary Lung Cancer 
syndrome Targets never 
smokers with Germline 
Egfr Gene T790m 
Mutations
carriers, all of who had non–small-cell lung cancer, were 
with one or more adenocarcinomas, ground-glass and 
solid nodular lesions, and associated with preinvasive 
lesions. Of the 22 tumors tested, 73% had T790M 
germline mutation in addition to a second activating 
mutation. The findings also revealed a highly significant 
association between never smokers and lung cancer 
cases in germline T790M carriers (p = 3.2E-07). The 
authors also conducted analysis to detect EGFR and 
germline T790M mutations in Japanese patients using 
paired normal and tumor tissues from 627 patients with 
resected non–small-cell lung cancer before tyrosine 
kinase inhibitors or other therapies. Thirty-three percent 
of samples were positive for EGFR mutation whereas 
none of 627 samples were positive for germline T790M 
mutations. Without adjusting for ethnicity, the prevalence 
of germline T790M mutation in the general population is 
estimated to be less than one in 7500. From the findings 
on the proband and family pedigree, germline T790M 
mutation is a major cancer predisposition gene, with 
an estimated 31% risk for lung cancer in never-smoker 
carriers, which is greater than in heavy smokers with or 
without the mutation. The median age of the cancer cases 
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The acquisition of the EGFR T790M point mutation is the most 
common mechanism of resistance to EGFR tyrosine kinase 
inhibitors whereas de novo EGFR T790M mutations are rare. This 
report describes the findings of molecular analysis on synchronous 
lung tumors of a 44-year-old never smoker with no family history 
of lung cancer, who had genetic testing that led to the identification 
of a germline EGFR T790M mutation. The subsequent genetic 
testing of her unaffected relatives revealed two additional EGFR 
T790M germline carriers: her daughter, and mother who was 
diagnosed with metastatic lung adenocarcinoma after the initial 
test. Further analysis demonstrated that the proband’s tumors were 
This report describes the investigation of hereditary lung cancer in 
a 29-year-old female patient and her family pedigree, in addition 
to literature review to summarize the current knowledge of this 
familial form of lung cancer. The proband, with a smoking history of 
0.1 pack-years, has adenocarcinoma, preneoplastic and preinvasive 
lesions, harboring L858R mutation in exon 21 and a germline 
T790M mutation. Relevant history of five generations of her 
family and blood samples from members of three generations were 
collected for the T790M mutation testing. Combining proband’s 
family pedigree with the literature, 19 of a total of 29 mutation 
carriers developed lung cancer. Tumors arising in T790M germline 
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•	 Comparison of Clinical 
Outcomes After Gefitinib 
and erlotinib Treatment 
in non–small-Cell Lung 
Cancer Patients harboring 
an epidermal Growth 
factor receptor Mutation 
in either exon 19 or 21
were treated with gefinitib (n = 228) or erlotinib 
(n = 147). Gefitinib- and erlotinib-treated patients 
were pair-matched on sex, smoking history, Eastern 
Cooperative Oncology Group performance status and 
EGFR mutation types. The study population, with 
a median age of 58 years, consisted of 63.6% never 
smokers, 98.3% adenocarcinoma, and 90.9% with good 
Eastern Cooperative Oncology Group status (0, 1). No 
significant difference was observed between gefitinib- 
and erlotinib-treated groups in overall response rates (p 
= 0.575), disease control rates (p = 0.305), and median 
progression-free survival ( p = 0.056). Gefitinib and 
erlotinib were given as first-line treatment in 26% of 
242 patients. In these patients, no significant difference 
between the two groups was found in overall response 
rates (p = 0.431) and median progression-free survival 
(p = 0.507). The authors concluded that, taken together, 
similar efficacy from gefitinib and erlotinib treatments 
was demonstrated in advanced NSCLC with EGFR 
mutations. (p. 506)
was about 63 years, they were predominantly women, 
in both lung cancers with sporadic EGFR mutations and 
for germline T790M cases. Unaffected carriers with this 
mutation are at higher risk for developing lung cancer 
regardless of smoking status and should be closely 
monitored including low-dose computed tomography 
scans. (p. 456)
Data comparing the efficacy and safety of erlotinib and gefitinib 
are limited in patients with advanced non–small-cell lung cancer 
(NSCLC) harboring EGFR mutations. In this study, the authors 
retrospectively reviewed data and compared the clinical outcomes 
of 317 patients with recurrent or metastatic stage IIIB/IV NSCLC, 
who had exon 19 deletion or L858R mutation in exon 21, and 
•	 next-Generation 
sequencing reveals a 
novel nsclc ALk f1174v 
Mutation and Confirms  
ALk G1202r Mutation 
Confers high-Level 
resistance to Alectinib 
(Ch5424802/ro5424802) 
in ALk-rearranged nsCLC 
Patients Who Progressed 
on Crizotinib
more potent ALK inhibitor in clinical development. In 
addition, a second ALK+ NSCLC patient was reported 
to harbor a previously described secondary acquired 
mutation, ALK G1202R, using comprehensive NGS. 
This patient was also enrolled in the same phase 
II trial as the aforementioned patient and received 
alectinib treatment. However, ALK G1202R was 
shown to confer high-level resistance to alectinib with 
disease progression, validating in vitro findings in a 
patient for the first time. This report demonstrated 
that comprehensive genomic profiling using targeted 
NGS provides insights into resistant tumor population 
and additional underlying genetic abnormalities apart 
from secondary acquired mutations (S45 deletion 
in CTNNB1, and loss of CDKN2A/B and ARFRP1 
amplification in parallel with ALK F1174V and ALK 
G1202R, respectively). This would help guide treatment 
decisions in crizotinib-resistant ALK+ NSCLC patients 
using second-generation ALK inhibitors and other 
novel therapeutic intervention. (p. 549)
This brief report described the finding of a novel acquired 
secondary mutation in the anaplastic lymphoma kinase (ALK) 
gene, namely ALK F1174V in an ALK-rearranged (ALK+) 
non–small-cell lung cancer (NSCLC) patient, who was resistant 
to crizotinib after a prolonged partial response. The discovery 
was achieved using comprehensive next-generation sequencing 
(NGS). The patient is currently in a phase II trial for  crizotinib-
resistant ALK+ NSCLC patients receiving alectinib treatment, a 
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•	 Prognostic Impact of 
Paraneoplastic Cushing’s 
syndrome in small-Cell 
Lung Cancer
(82.6%, p = 0.005), more than two metastatic sites 
(63%; p ≤0.001), a higher World Health Organization 
performance status (2–4) (73.9%; p = 0.006), greater 
weight loss of 10% or more (47.8%; p ≤0.001), 
reduced objective response (47.6%, p = 0.04) and 
poorer sensitivity (19%, p = 0.01) to first-line therapy. 
CushingPS patients had a median survival of 6.6 months 
versus 9.2 months (OtherPS) and 13.1 months (NoPS) 
(p ≤ 0.001). It was also shown that the NoPS group 
with World Health Organization performance status of 
3 to 4 exhibited similar extensive disease, response and 
sensitivity to first-line treatment, and survival to the 
CushingPS group. CushingPS patients demonstrated no 
objective response to second-line treatment on relapse 
(p = 0.005). To conclude, CushingPS is a prognostic 
factor of death with a hazard ratio of 2.31 (p ≤ 0.001). It 
is correlated to extensive tumors in SCLC patients with 
poor performance status and dramatic weight loss. Their 
lowered objective response and sensitivity to first-line 
therapy and nonresponsiveness to second-line therapy 
indicate early palliative care at first-line treatment and 
only palliative care at relapse. (p. 497)
research Watch
•	 A Correlative MILd Trial 
study: Plasma mirnA 
signature Classifier in 
Computed Tomography 
Lung Cancer screening
In search of complementary biomarkers to potentially 
reduce the false-positive rates of low-dose computed 
tomography (LDCT) for lung cancer screening, the 
authors conducted a retrospective study on the diagnostic 
performance of a noninvasive plasma microRNA 
signature classifier (MSC) in plasma samples collected 
from smokers (n = 939) in the randomized Multicenter 
Italian Lung Detection trial. Quantitative  reverse-
transcriptase polymerase chain reaction–based assay for 
MSC was used to examine samples from lung cancer 
patients and disease-free participants in LDCT arm  
(n = 652) and observation arm (n = 287). A blinded 
validation study was used to analyze diagnostic 
performance of MSC. The results demonstrated 87% 
sensitivity and 81% specificity using MSC to detect lung 
cancer in both arms, with 88% and 80%, respectively, in the 
LDCT arm. MSC also showed 99% and 99.86% of negative 
predictive value for detection and death from the disease, 
respectively. In addition to better sensitivity and similar 
specificity to LDCT alone (79% and 81%, respectively), 
MSC plus LDCT reduced LDCT false-positive rate by 
fivefold (19.4%–3.7%). A significant correlation with 
survival was also observed in MSC risk groups (p < 0.001). 
Taken together, the findings demonstrated the predictive, 
diagnostic, and prognostic value of MSC with the potential 
of reducing the false-positive rate of LDCT.
Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a 
plasma-based miRNA signature classifier within computed 
tomography lung cancer screening: a correlative MILD Trial 
Study. J Clin Oncol 2014; doi:10.1200/jco.2013.50.4357.
Paraneoplastic Cushing’s syndrome (CushingPS) is rare but severe 
in small-cell lung cancer (SCLC). The authors conducted a 14-year 
retrospective study to assess the impact of CushingPS in SCLC 
regarding presentation, response to treatment and survival, as 
well as to determine potential treatment strategy for the disease at 
different stages. Of 383 SCLC patients, CushingPS was found in 
23, other paraneoplastic syndrome (OtherPS) in 56, and 304 had no 
paraneoplastic syndrome (NoPS). In comparison with patients with 
OtherPS and NoPS, CushingPS patients had more extensive disease 
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•	 Lux-Lung 6 Trial: Afatinib 
Improves Progression-free 
survival in Asian Patients 
With Egfr-Mutation–
Positive Advanced 
nsCLC Compared With 
Gemcitabine/Cisplatin as 
first-Line Treatment
months; p < 0.0001). Objective response was observed 
in 66.9% versus 23.0% of patients, respectively, (odds 
ratio = 7.28, p < 0.0001). Rash or acne, diarrhea, 
and stomatitis or mucositis were the most common 
treatment-related grade 3 or 4 toxicity in the afatinib 
arm versus vomiting, neutropenia, and leucopenia in the 
gemcitabine plus cisplatin arm. Treatment-related severe 
adverse events occurred in 6.3% of the afatinib group 
versus 8.0% of the gemcitabine plus cisplatin group. 
Taken together, this study demonstrated that first-line 
afatinib improves progression-free survival and objective 
response rate, with a tolerable safety profile versus the 
gemcitabine plus cisplatin regimen in Asian patients with 
EGFR-positive advanced NSCLC.
Wu YL, Zhou C, Hu C-P, et al. Afatinib versus 
cisplatin plus gemcitabine for first-line treatment of 
Asian patients with advanced non-small-cell lung 
cancer harbouring EGFR mutations (LUX-Lung 6): 
an open-label, randomised phase 3 trial. Lancet Oncol 
2014;15:213–222.
Studies have demonstrated a survival benefit from afatinib, an 
irreversible inhibitor of the ErbB family, when compared with 
pemetrexed and cisplatin as first-line treatment in EGFR-mutation–
positive advanced non–small-cell lung cancer (NSCLC) patients. In 
the phase III LUX-Lung 6 trial, Wu et al. set out to compare afatinib 
with the widely used chemotherapy regimen in Asia, gemcitabine 
plus cisplatin, as first-line in treatment-naive Asian patients with 
stage IIIB/IV NSCLC harboring EGFR mutation. The primary 
endpoint was progression-free survival. In the 364 randomized 
patients, the afatinib arm showed significantly longer median 
survival (11.0 months) versus the gemcitabine plus cisplatin arm (5.6 
•	 Lume-Lung 1: docetaxel 
Plus nintedanib versus 
docetaxel Plus Placebo 
in Previously Treated 
non–small-Cell Lung 
Cancer Patients
The phase III, double-blind, randomized controlled trial, 
LUME-Lung 1, aimed to evaluate the efficacy and safety of 
adding nintedanib to docetaxel as a second-line treatment 
for patients with stage IIIB/IV recurrent non–small-cell 
lung cancer progressing after first-line chemotherapy. The 
primary endpoint was progression-free survival and the key 
secondary endpoint was overall survival. After a median 
follow-up of 7.1 months, the docetaxel plus nintedanib 
arm achieved a significantly improved progression-free 
survival of 3.4 months versus 2.7 months in the docetaxel 
plus placebo arm (p = 0.0019). The addition of nintedanib 
to docetaxel significantly improved overall survival in 
patients with adenocarcinoma, whose disease progressed 
within 9 months after first-line treatment (median 10.9 
months versus 7.9 months; p = 0.0073), and in all patients 
with adenocarcinoma (median 12.6 months versus 10.3 
months; p = 0.0359). Diarrhea, reversible rise in alanine 
aminotransferase and aspartate aminotransferase were 
more common grade 3 or higher adverse events in the 
nintedanib combination group. Deaths were reported 
in the nintedanib combination group (n = 35) and the 
docetaxel/placebo group (n = 25), possibly unrelated to 
tumor progression. To conclude, the study indicated that 
the addition of nintedanib to docetaxel shows survival 
benefit as a second-line treatment for advanced non– small-
cell lung cancer patients with one prior platinum-based 
treatment, and of adenocarcinoma in particular.
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus 
nintedanib versus docetaxel plus placebo in patients 
with previously treated non-small-cell lung cancer 
(LUME-Lung 1): a phase 3, double-blind, randomised 
controlled trial. Lancet Oncol 2014;15:143–155.






in  Crizotinib-Treated 
ALk-Positive Lung Cancer 
Patients
local control rate of 100% and 60%, respectively (p 
= 0.01) with neither acute toxicities nor toxicities 
that were higher than grade 2. Patients receiving LAT 
continued to take crizotinib for a median overall time 
of 28 months versus 10.1 months in those whose 
disease had progressed and was not suitable for LAT. A 
prolonged 2-year survival rate was achieved in patients 
continuing on crizotinib for more than 12 months (72%) 
versus 12 months or lesser (12%; p < 0.0001). Taken 
together, LAT is safe and durable in suppressing OPD 
in ALK-positive NSCLC patients taking crizotinib, 
which enabled these patients to continue on crizotinib 
treatment for overall condition and led to improved 
2-year survival rates versus those forced to discontinue 
the drug sooner.
Gan GN, Weickhardt AJ, Scheier B, et al. 
Stereotactic radiation therapy can safely and 
durably control sites of extra-central nervous system 
oligoprogressive disease in anaplastic lymphoma 
kinase-positive lung cancer patients receiving crizotinib. 
Internat J Rad Oncol*Biol*Phys, doi:http://dx.doi.
org/10.1016/j.ijrobp.2013.11.010.
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•	 A simple and Accurate 
Test of exhaled Breath May 
help detect early Lung 
Cancer
(collectively known as carbonyls). The findings were 
presented at the 50th Annual Meeting of The Society 
of Thoracic Surgeons in Orlando, Florida. Increased 
levels of three or four carbonyls were associated with 
lung cancers in 95% of patients whereas normal levels 
of these compounds were associated with benign 
growth in 80% of patients. The authors also found that 
increased levels of carbonyl dropped to normal after 
tumor resection in lung cancer patients. This study 
suggests that this new approach using exhaled breath, 
which is simple to be collected and easy for patients, 
could accurately determine which patients to be sent 
for invasive biopsy and resection after discovering a 
suspicious lesion on computed tomography scans.
Photo credit: Pulmonary Pathology http://www.flickr.
com/photos/pulmonary_pathology/6327961286/in/
photostream/
This study evaluated the safety and durability of using 
radiotherapeutic local ablative therapy (LAT) to treat extracentral 
nervous system (eCNS) disease progression in anaplastic lymphoma 
kinase (ALK)–positive non–small cell lung cancer (NSCLC) 
patients. ALK-positive NSCLC patients treated with crizotinib were 
classified as having oligoprogressive disease (OPD) when there 
were four or fewer discrete sites of eCNS progression. Additional 
LAT courses were given to these patients, who continued on 
crizotinib until eCNS disease progressed beyond OPD criteria or 
not suitable for additional LAT. Of 33 patients with progressive 
disease on crizotinib, 14 met OPD criteria for LAT and received up 
to three courses of LAT. Local lesion control rates with LAT were 
100% (6 months) and 86% (12 months). Single-fraction equivalent 
dose of more than 25 Gy and 25 Gy or lesser achieved a 12-month 
Bousamra and colleagues from the University of Louisville 
examined exhaled breath from individuals detected with 
suspicious lung lesions on computed tomography scans. A silicone 
microprocessor and mass spectrometer was used to test the 
breath for levels of cancer-specific volatile organic compounds 
